Comparative Pharmacology
Head-to-head clinical analysis: PORCINE SECRETIN versus PYLORI CHEK BREATH TEST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PORCINE SECRETIN versus PYLORI CHEK BREATH TEST.
PORCINE SECRETIN vs PYLORI-CHEK BREATH TEST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stimulates exocrine pancreatic secretion by acting on secretin receptors on pancreatic ductal cells, increasing bicarbonate and water secretion. Also stimulates bile and gastric acid secretion.
Urea labeled with 13C is hydrolyzed by urease enzyme produced by Helicobacter pylori, producing 13CO2 which is exhaled and detected in breath.
0.2 mcg/kg intravenous bolus over 1 minute, maximum 20 mcg.
Adults: 75 mg of 13C-urea dissolved in 75 mL of water, administered orally as a single dose. Breath samples collected at baseline and 30 minutes post-dose.
None Documented
None Documented
The terminal elimination half-life is approximately 4-6 minutes, reflecting rapid degradation by plasma proteases; this short half-life limits its systemic duration of action and necessitates continuous infusion for sustained secretory testing.
The elimination half-life of 13C-urea is approximately 0.5–1 hour in patients with normal renal function, reflecting rapid renal clearance. In severe renal impairment, half-life may be prolonged up to 7–10 hours.
Primarily renal, with over 90% of the administered dose eliminated via glomerular filtration and tubular reabsorption; fecal and biliary excretion are negligible.
13C-urea is excreted renally as intact urea (approximately 85%) and as 13CO2 in breath (approximately 15%). Fecal elimination is negligible. In renal impairment, breath 13CO2 excretion may increase as renal clearance decreases.
Category C
Category C
Diagnostic Agent
Diagnostic Agent